NASDAQ
341.75USD
-9.13 (-2.60%)
We have scored 18 news catalysts on Krystal Biotech, Inc. (KRYS) over the past 12 months. The biggest single-day move next to one of them came May 10, 2026, when KRYS closed +3.0%: “Krystal Biotech: Vyjuvek Is Not The Primary Asset”. Coverage across the window leans positive (average ticker sentiment +0.71). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.1B
P/E
—
EPS
—
Beta
0.54
52W range
158.08-382.535
Day range
337.75–353.84
Open
353.84
Prev close
350.88
Volume
215.9K
Avg volume
367.9K
Dividend
0.00
IPO
2017-09-20
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Krystal Biotech, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KRYS: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
